Eli Lilly is in advanced talks to acquire gene editing startup Verve Therapeutics for up to $1.3 billion, aiming to ...

Eli Lilly is in late-stage talks to purchase Verve Therapeutics in a transaction that could total $1.3 billion, according to ...

As part of the deal, Eli Lilly would pay almost $1bn upfront for Verve, which is developing a gene-editing therapy to treat bad cholesterol, and a further $300mn based on the biotech company achieving ...

Eli Lilly and Company (NYSE: LLY) is reportedly in advanced talks to acquire gene editing biotech Verve Therapeutics Inc.

Similarly, VERV’s pipeline includes VERVE-201 for HoFH and refractory hypercholesterolemia, as well as VERVE-301 in collaboration with Lilly ... Verve Therapeutics is currently based in ...

Verve Therapeutics saw its stock surge by more than 26% when markets opened today (14 April) after the company announced early-stage clinical data for its Eli Lilly-partnered experimental gene ...

Verve Therapeutics shares were 8% higher ... delivery of research services under the company's collaboration with Eli Lilly. Verve said it had cash, cash equivalents, and marketable securities ...

Verve Therapeutics has won U.S. Food and Drug Administration ... stage genetic-medicines company in 2023 struck a deal with Eli Lilly that gave Lilly the right to opt-in to share 33% of worldwide ...

Verve Therapeutics is at the forefront of a new ... Partnership with Eli Lilly: Verve’s collaboration with Eli Lilly (NYSE:LLY) is a significant asset for the company. Analysts anticipate ...

Verve Therapeutics, a clinical-stage company developing a new class of genetic medicines for cardiovascular disease, today reported pipeline updates and financial results for the first quarter ...